Topiramate-associated acute, bilateral, secondary angle-closure glaucoma.

Purpose: To evaluate spontaneous reports of ocular side effects associated with topiramate use.

Design: Retrospective case series.

Methods: One hundred fifteen case reports, primarily of a specific ocular syndrome (acute secondary angle-closure glaucoma), were collected from spontaneous reporting systems: the Drug Safety section of Ortho-McNeil Pharmaceuticals, Inc.

Comparison of phacotrabeculectomy with 5-fluorouracil, mitomycin-C, and without antifibrotic agents.

Background And Objective: To evaluate the potential benefits, complications, and prognostic risk factors for failure of phacotrabeculectomy performed with or without 5-fluorouracil (5-FU) and mitomycin-C (MMC).

Patients And Methods: Retrospective chart review of 78 patients who underwent phacotrabeculectomy during a 2-year period. Patients were divided into 3 groups, those who received 5-FU (N = 28).

Timolol hemihydrate vs timolol maleate to treat ocular hypertension and open-angle glaucoma.

Purpose: We compared the therapeutic efficacy and safety of timolol hemihydrate to timolol maleate in patients with ocular hypertension and chronic open-angle glaucoma.

Methods: We conducted this three-month study as a multicentered, masked, parallel group comparison. Both the 0.

Carteolol hydrochloride: controlled evaluations of its ocular hypotensive efficacy relative to its vehicle, and, in combination with pilocarpine, relative to timolol.

Carteolol is a noncardioselective beta-adrenoceptor antagonist with intrinsic sympathomimetic activity. In the two studies presented in this report, we sought (a) to evaluate the absolute efficacy of carteolol (i.e.

Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level.

Fifty-eight healthy, normolipidemic adult men participated in a prospective, masked, randomized crossover study designed to compare the effects of two topical nonselective beta-adrenergic antagonists, carteolol and timolol, on plasma high-density lipoprotein cholesterol levels. Two eight-week treatment periods were separated by an eight-week drug-free period. Carteolol 1.